Literature DB >> 15997228

Functional expression of the P2Y14 receptor in murine T-lymphocytes.

Michelle Scrivens1, John M Dickenson.   

Abstract

Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) analysis has previously shown that the P2Y(14) receptor is expressed in peripheral immune cells including lymphocytes. Although in transfected cells the P2Y(14) receptor couples to pertussis toxin-sensitive G(i/o) protein, the functional coupling of endogenously expressed P2Y(14) receptors to the inhibition of adenylyl cyclase activity has not been reported. Therefore, the primary aim of this study was to determine whether the P2Y(14) receptor is functionally expressed in murine spleen-derived T- and B-lymphocyte-enriched populations. RT-PCR analysis detected the expression of P2Y(14) receptor mRNA in whole spleen and isolated T- and B-lymphocytes. In T cells, UDP-glucose (EC(50) = 335 nM) induced a small but significant inhibition (circa 20%) of forskolin-stimulated cAMP accumulation, suggesting functional coupling of endogenously expressed P2Y(14) receptors to the inhibition of adenylyl cyclase activity. In contrast, the other putative P2Y(14) receptor agonists UDP-galactose, UDP-glucuronic acid and UDP-N-acetylglucosamine had no significant effect alone but behaved as partial agonists by blocking UDP-glucose responses. In B cells, UDP-glucose (100 microM) had no significant effect on forskolin-stimulated cAMP accumulation. Treatment of T cells with pertussis toxin (G(i/o) blocker) abolished the inhibitory effects of UDP-glucose on forskolin-stimulated cAMP accumulation. T-cell proliferation in response to anti-CD3 monoclonal antibody (1 microg ml(-1)) was significantly inhibited by UDP-glucose (59% inhibition; p[IC(50)] = 5.9 +/- 0.3), UDP-N-acetylglucosamine (37%; 6.1 +/- 0.3), UDP-galactose (56%; 8.2 +/- 0.2) and UDP-glucuronic acid (49%; 6.3 +/- 0.2). Interleukin-2- (5 ng ml(-1)) induced T-cell proliferation was also significantly inhibited by all four agonists. In summary, we have shown that the P2Y(14) receptor appears to be functionally expressed in murine spleen-derived T-lymphocytes. These observations suggest that UDP-glucose and related sugar nucleotides presumably via the P2Y(14) receptor may play an important role in modulating immune function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15997228      PMCID: PMC1576276          DOI: 10.1038/sj.bjp.0706322

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Influence of rolipram on the cyclic 3',5'-adenosine monophosphate response to histamine and adenosine in slices of guinea-pig cerebral cortex.

Authors:  J Donaldson; A M Brown; S J Hill
Journal:  Biochem Pharmacol       Date:  1988-02-15       Impact factor: 5.858

Review 2.  JAK/STAT signaling by cytokine receptors.

Authors:  K D Liu; S L Gaffen; M A Goldsmith
Journal:  Curr Opin Immunol       Date:  1998-06       Impact factor: 7.486

3.  The isolation and characterization of a novel G protein-coupled receptor regulated by immunologic challenge.

Authors:  M E Charlton; A S Williams; M Fogliano; P M Sweetnam; R S Duman
Journal:  Brain Res       Date:  1997-08-01       Impact factor: 3.252

4.  Prediction of the coding sequences of unidentified human genes. I. The coding sequences of 40 new genes (KIAA0001-KIAA0040) deduced by analysis of randomly sampled cDNA clones from human immature myeloid cell line KG-1.

Authors:  N Nomura; N Miyajima; T Sazuka; A Tanaka; Y Kawarabayasi; S Sato; T Nagase; N Seki; K Ishikawa; S Tabata
Journal:  DNA Res       Date:  1994       Impact factor: 4.458

5.  Characteristics of the Ca(2+)-dependent inhibition of cyclic AMP accumulation by histamine and thapsigargin in human U373 MG astrocytoma cells.

Authors:  M P Wong; D M Cooper; K W Young; J M Young
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

6.  A G protein-coupled receptor for UDP-glucose.

Authors:  J K Chambers; L E Macdonald; H M Sarau; R S Ames; K Freeman; J J Foley; Y Zhu; M M McLaughlin; P Murdock; L McMillan; J Trill; A Swift; N Aiyar; P Taylor; L Vawter; S Naheed; P Szekeres; G Hervieu; C Scott; J M Watson; A J Murphy; E Duzic; C Klein; D J Bergsma; S Wilson; G P Livi
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

7.  Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion.

Authors:  S Huang; S Apasov; M Koshiba; M Sitkovsky
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

8.  Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.

Authors:  Andreas A Erdmann; Zhan-Guo Gao; Unsu Jung; Jason Foley; Todd Borenstein; Kenneth A Jacobson; Daniel H Fowler
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

9.  Expression of the P2Y6 purinergic receptor in human T cells infiltrating inflammatory bowel disease.

Authors:  G R Somers; F M Hammet; L Trute; M C Southey; D J Venter
Journal:  Lab Invest       Date:  1998-11       Impact factor: 5.662

10.  Analysis of calcium responses mediated by the A3 adenosine receptor in cultured newborn rat cardiac myocytes.

Authors:  Vladimir Shneyvays; Tova Zinman; Asher Shainberg
Journal:  Cell Calcium       Date:  2004-11       Impact factor: 6.817

View more
  28 in total

Review 1.  Signalling and pharmacological properties of the P2Y receptor.

Authors:  T K Harden; J I Sesma; I P Fricks; E R Lazarowski
Journal:  Acta Physiol (Oxf)       Date:  2010-03-24       Impact factor: 6.311

2.  GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity.

Authors:  Jianfeng Xu; Hidetaka Morinaga; Dayoung Oh; Pingping Li; Ai Chen; Saswata Talukdar; Yaël Mamane; Joseph A Mancini; Andrea R Nawrocki; Eduardo Lazarowski; Jerrold M Olefsky; Jane J Kim
Journal:  J Immunol       Date:  2012-07-09       Impact factor: 5.422

3.  The inflammatory effects of UDP-glucose in N9 microglia are not mediated by P2Y14 receptor activation.

Authors:  Vielska M Brautigam; George R Dubyak; Jessica M Crain; Jyoti J Watters
Journal:  Purinergic Signal       Date:  2008-02-08       Impact factor: 3.765

4.  From quiescence to senescence.

Authors:  Byeong Chel Lee; David T Scadden
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 5.  Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses.

Authors:  Fenila Jacob; Claudina Pérez Novo; Claus Bachert; Koen Van Crombruggen
Journal:  Purinergic Signal       Date:  2013-02-13       Impact factor: 3.765

Review 6.  UDP-Sugars as Extracellular Signaling Molecules: Cellular and Physiologic Consequences of P2Y14 Receptor Activation.

Authors:  Eduardo R Lazarowski; T Kendall Harden
Journal:  Mol Pharmacol       Date:  2015-03-31       Impact factor: 4.436

7.  Selective induction of P2Y14 receptor by RANKL promotes osteoclast formation.

Authors:  Seung Ah Lee; Jin Hee Park; Soo Young Lee
Journal:  Mol Cells       Date:  2013-09-17       Impact factor: 5.034

Review 8.  The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism.

Authors:  Guido Beldi; Keiichi Enjyoji; Yan Wu; Lindsay Miller; Yara Banz; Xiaofeng Sun; Simon C Robson
Journal:  Front Biosci       Date:  2008-01-01

9.  The G protein-coupled receptor P2Y14 influences insulin release and smooth muscle function in mice.

Authors:  Jaroslawna Meister; Diana Le Duc; Albert Ricken; Ralph Burkhardt; Joachim Thiery; Helga Pfannkuche; Tobias Polte; Johannes Grosse; Torsten Schöneberg; Angela Schulz
Journal:  J Biol Chem       Date:  2014-07-03       Impact factor: 5.157

10.  Endoplasmic reticulum/golgi nucleotide sugar transporters contribute to the cellular release of UDP-sugar signaling molecules.

Authors:  Juliana I Sesma; Charles R Esther; Silvia M Kreda; Lisa Jones; Wanda O'Neal; Shoko Nishihara; Robert A Nicholas; Eduardo R Lazarowski
Journal:  J Biol Chem       Date:  2009-03-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.